| Product | Clinical Indication | Phase of Development | Partner | Anticipated Newsflow |
| Juvista EU | Prophylactic improvement of skin scar appearance | PhIII in scar revision surgery (1st of 2 efficacy trials for approval) | - | Q4 2010 paediatric formulation trial reports H1 2011 1st pivotal EU PhIII trial in scar revision surgery reports |
| Juvista US | Prophylactic improvement of skin scar appearance | PhII | Shire | Q4 2010 earlobe keloid pilot trial reports |
| Adaprev | Reduction of adhesions following digital tendon injury | Class III medical device Safety and preliminary performance (1st of 2 trials for approval) | - | H1 2011 trial reports |
| Prevascar | Reduction of skin scarring | PhII | - | Q2 2010 PhII clinical trial in African subjects commences |
| Juvidex | Improve skin appearance and promote healing of damaged skin | Cosmetic ingredient Out-license | - | 2010 out-license/partner |
| RN1005 | Prevent scarring and enhance tissue regeneration | Preclinical | - | 2010 Progress development. TSB grant |
